Technology
Health
Medical

AtriCure

$28.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (0.03%) Today
+$0.01 (0.03%) Today

Why Robinhood?

You can buy or sell AtriCure and other stocks, options, ETFs, and crypto commission-free!

About

AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. Read More It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.

Employees
620
Headquarters
Mason, Ohio
Founded
2000
Market Cap
1.11B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
208.77K
High Today
$28.70
Low Today
$28.48
Open Price
$28.68
Volume
2.40K
52 Week High
$36.49
52 Week Low
$19.22

Collections

Technology
Health
Medical
US
North America

News

MarketBeatMar 8

Stock Price, News, & Analysis for AtriCure

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar ...

6
StreetInsiderMar 4

Axonics Modulation Technologies Inc. (AXNX) Announces Michael H. Carrel to Board

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Michael H. Carrel has been appointed to the Axonics board of directors, effective immediately. Mr. Carrel has served as the president and CEO and member of the board of AtriCure, Inc. (NASDAQ: ATRC) since late 2012. AtriCure is a medical device co...

3
Seeking AlphaMar 1

AtriCure files for mixed shelf and sale of stock by current investors

AtriCure (ATRC +0.2% ) has filed a prospectus for an unspecified mixed shelf offering and the potential sale of up to 5,659,984 common shares by current stockholders.

17

Earnings

-$0.31
-$0.23
-$0.16
-$0.08
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 25, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.